ABSTRACT Lead and zinc concentrations in plasma, erythrocytes, and urine, urinary ALA concentration, and ALA-D activity in blood were studied for four hours in two male lead workers during and after a one hour infusion of Ca-EDTA 2Na. Urinary and plasma lead concentrations increased as a result of administering Ca-EDTA 2Na, and the ratios of lead concentrations in plasma to those in urine were greatly increased. The increase of plasma lead concentration was not due to the haemolytic effect of Ca-EDTA 2Na but was mobilised lead, rapidly excreted in the urine. ALA-D activity in blood increased at the end of the experiment with a transient decrease during the infusion of Ca-EDTA 2Na. As zinc concentrations in erythrocytes and plasma did not decrease during the infusion despite an increase in the urinary excretion of zinc, the transient decrease of ALA-D activity was not due to a loss of zinc caused by Ca-EDTA 2Na. From the results of additional experiments in vitro, this transient decrease could be related neither to Ca-EDTA 2Na nor to lead in the blood.
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The effects of intravenous infusion of calcium disodium ethylene diamine tetra-acetate (Ca-EDTA 2Na) on the elimination of lead from the body have been well studied. '-8 In most studies'-578 the lead concentration in the whole blood has been determined, and attention has been given mainly to the changes reflecting lead absorption. The selective determination of plasma lead concentrations is of great importance for the study of the urinary excretion of lead but is found in few reports.69 McRoberts observed that plasma lead concentrations decreased 2.5 hours after the administration of Ca-EDTA 2Na with a clear increase in urinary lead excretion,6 but he did not study the time course of the lead concentrations in the early stages after the initiation of the Ca-EDTA 2Na infusion. Few detailed data for the urinary excretion of lead in the early phase of Ca-EDTA 2Na infusion are available. Therefore, we have examined the time course of lead concentrations in plasma, erythrocytes, and urine in the early stages of the lead mobilisation test by Ca-EDTA 2Na.
The inhibition of delta aminolaevulinic acid Twenty millilitres of urine were digested by the addition of an acid mixture (5 ml of 14-9 N nitric acid, 1 ml of 11.7 N perchloric acid, and 1 ml of 36 N sulfric acid). The digested samples were diluted to 10 ml by doubly distilled water, and taking 10 ,ul of the diluted samples, the urinary lead concentration was determined by flameless atomic absorption spectrophotometry (Jarrel-Ash, AA Ishihara, Shiojima, and Hasegawa 8200 and FLA 100). The minimum detectable amount of lead in our laboratory was 2-4 pmoles of lead, and the coefficient of variation was 2-9%. Blood samples were centrifuged at 3000 rpm for 15 minutes immediately after sampling. After removing the plasma, doubly distilled water was added to the erythrocytes to obtain a haemolysate equal to that of the sampling volume. Two millilitres of plasma or 5 ml of haemolysate were digested by the same procedure as that used for the urine and the digested samples were diluted to 10 ml by doubly distilled water; lead concentrations in 20 ,ul of the diluted sample were determined by the method used for the unne.
ZINC DETERMINATIONS
Using the digested and diluted samples of urine, plasma, and erythrocytes, zinc concentrations were determined by flame atomic absorption spectrophotometry (Perkin-Elmer, Model 370). The minimum detectable concentration of zinc in our laboratory was 9 nmoles of Zn/ml of digested and diluted sample.
ASSAY OF ALA-D ACTIVITY
The activity of ALA-D was assayed by the European standard method'5 using 0 1 ml of heparinised blood. decreased by the addition of Ca-EDTA 2Na to a final concentration of 2-5 x 10-5M or more, but the decrement of ALA-D activity is about 10-20% of the control activity. Another experiment in vitro ( fig  5) indicates that the inhibition of ALA-D activity by added inorganic lead is about 10% at the final concentration between 5-0 x 10-8M and 10-6M; 50% inhibition is achieved at 5-0 x 10-5M. Pretreatment of the whole blood or erythrocytes suspension with Ca-EDTA 2Na at a final concentration between 10-6M to 10-3M did not reduce ALA-D activity. McRoberts reported a fall in plasma lead concentrations after Ca-EDTA2Na administration to lead workers,6 but he did not determine the plasma lead concentration before the Ca-EDTA 2Na treatment was begun nor did he examine the time course of lead concentrations in the early stages of the treat- The possibility of the inhibition by the carry-in of lead in plasma should be examined. The maximum lead concentration in the plasma in subject 1 is 0-16 nmoles/ml, and his haematocrit value is 45%. Therefore, the maximum increment of lead concentration in the assay system for the ALA-D activity due to carry-in is about 4 x 10-9M. Figure 5 indicates that the decrement of the ALA-D activity is about 10% in the presence of added inorganic lead at a final concentration of 10-7M. Therefore, the decrease of ALA-D activity during the infusion seems not to result from the carry-in of lead in the plasma. The mechanism of the reduction of ALA-D activity during the infusion cannot be explained completely at present and is under further investigation.
Chisolm (fig 1) , the urinary ALA concentration does not decrease four hours after treatment. This discrepancy between our observation and others might be dependent on the difference of the exposure level for the subject. 
